Ccr5 Δ32 Mutation - Infectious Diseases

Relevant Publications

The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.

Issue Release: 2024

Exploring the Association of Biochemical Characterization and Genetic Determinants of TNF-α, CXCR2, and CCR5 Delta 32 Mutation with Predisposition to Polycystic Ovary Syndrome.

Issue Release: 2024

A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.

Issue Release: 2024

CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.

Issue Release: 2024

Dual effect of C-C motif chemokine receptor 5 on ischemic stroke: More harm than benefit?

Issue Release: 2023

Biallelic, Selectable, Knock-in Targeting of CCR5 CRISPR-Cas9 Mediated Homology Directed Repair Inhibits HIV-1 Replication.

Issue Release: 2022

CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair.

Issue Release: 2022

CCR5-Δ32 polymorphism - a possible protective factor from gait impairment among post-stroke patients.

Issue Release: 2022

Clinical parameters, selected HLA and chemokine gene variants associated with late presentation into care of people living with HIV/AIDS.

Issue Release: 2021

CCR5-Δ32 polymorphism: a possible protective factor for post-stroke depressive symptoms.

Issue Release: 2021

Frequency of CCR5-Δ32, CCR2-64I and SDF1-3\'A alleles in HIV-infected and uninfected patients in Istanbul, Turkey.

Issue Release: 2021

Evaluation of CCR5-Δ32 mutation among individuals with high risk behaviors, neonates born to HIV-1 infected mothers, HIV-1 infected individuals, and healthy people in an Iranian population.

Issue Release: 2020

Virus-Specific T Cell Therapies for HIV: Lessons Learned From Hematopoietic Stem Cell Transplantation.

Issue Release: 2020

Does the CCR5-Δ32 mutation explain the variable coronavirus-2019 pandemic statistics in Europe?

Issue Release: 2020

Generation of a human iPSC line (IMEDEAi008-A) derived from natural homozygous CCR5-Δ32 PBMCs enriched in the pro-erythroblast population.

Issue Release: 2020

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.

Issue Release: 2019

Designer Nucleases: Gene-Editing Therapies using CCR5 as an Emerging Target in HIV.

Issue Release: 2019

\"Here Today, Gone Tomorrow\" or \"Here Today, Stay a Long While\": The Divergent Paths of Two Host Factors Important in Viral Infections.

Issue Release: 2019

Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV.

Issue Release: 2019

CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury.

Issue Release: 2019

How Does WHO Collaborate with Other Organizations?

What is Vaccine Hesitancy?

How Are Infectious Diseases Transmitted in Animals?

Why is Immune System Stimulation Important?

What Are Parasitic Infections?

How Do HDAC Inhibitors Work?

What are Receptors?

How is Gonorrhea Transmitted?

Why is Folate Biosynthesis a Target for Antibiotics?

What are the Common Barriers to Vaccination?

Partnered Content Networks

Relevant Topics